ERITROPOYETINA HUMANA RECOMBINANTE PDF

| | 0 Comments

Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.

Author: Akisida Shakat
Country: Suriname
Language: English (Spanish)
Genre: Travel
Published (Last): 2 August 2017
Pages: 388
PDF File Size: 20.42 Mb
ePub File Size: 13.48 Mb
ISBN: 567-9-40378-564-9
Downloads: 24826
Price: Free* [*Free Regsitration Required]
Uploader: Fenrikree

Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. NDT Plus ;2 Suppl 1: Among the remaining 96 patients 40 BEN and 56 others who met inclusion criteria, 10 with BEN and hkmana with other kidney diseases were selected using systematic sampling i.

A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection. Population pharmacokinetics of erythropoietin in critically ill subjects. Pharmacokinetics For pharmacokinetic analysis the predose plasma level of Epo was subtracted from all postdose levels of Epo for each patient.

In addition, none of the mentioned factors for Epo hyporesponsiveness were significantly more pronounced in BEN than in non-BEN patients, except for older age. Results of laboratory analyses in the examined individuals are given in Table 2.

J Am Soc Nephrol ;5: As previous studies showed that the kidneys contribute to Epo elimination in a very minor fashion 35 and residual kidney function in patients more than three years on dialysis is most often negligible, it is not expected that renal elimination of Epo eritropoyeitna be of any influence. Similar inter-individual differences were found in time needed to reach Epo C max.

  ALIMAK SCANDO 450 PDF

Eritropoyetina Humana Recombinante

When adjusted these differences remained statistically significant 0. Venous blood was collected into heparinized tubes before and at 2, 6, 8, 12, 24, 48, and 72 only in five patients h after beta-Epo administration.

Clin J Eritropoyetiha Soc Nephrol ;3: The group with other kidney diseases consisted of 8 patients with glomerulonephritis, 3 with hypertensive nephropathy, 2 with reflux nephropathy and 1 with polycystic kidney disease.

Pavlovic-Kentera V, Djukanovic Lj. Ingredient matches for Eritropoyetina Humana Recombinante Erythropoietin Erythropoietin is reported as an ingredient of Eritropoyetina Humana Recombinante in the following countries: However, several authors reported no significant differences humans anemia in BEN and other kidney diseases. Srp arh cel lek ; In addition, recently described mechanisms independent of the Epo receptor elimination pathway, 29 may also contribute to slower Epo elimination in BEN patients.

Introduction Anemia was described as a characteristic of Balkan endemic nephropathy BEN in early reports on the disease, 1,2 so Danilovic 3 included it among the criteria for diagnosis. Basal plasma Epo concentration in BEN patients ranged between 7. The originating document has been archived. Colombia Hmana information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

  ANASAKTI YOGA GANDHI PDF

It should not be construed editropoyetina indicate that the use of any medication in any country is safe, appropriate or effective for you. The results were expressed as mean values with standard deviations. BEN is a slow progressive chronic kidney disease eritgopoyetina patients who progress to end-stage renal disease usually start hemodialysis in the seventh decade of life.

Consult with your healthcare professional before taking any medication.

Eritropoyetina Humana Recombinante Delta –

Djukanovic Lj, Radovanovic Z. No significant differences between groups were found in maximal Epo concentration, time to maximum Epo concentration, area under the curve from time of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before recombinajte after adjustment. Available for Android and iOS devices.

Our patients had iron reserves above the upper limit of normal and a similar proportion of subjects from each group used iron supplements. Nonerythropoietin receptor-mediated pathways may play a major role. We comply with the HONcode standard for trustworthy health information – verify here.

Erythropoietin and anemia in the progression of Balkan endemic nephropathy and other renal diseases.